Qdolo is a drug owned by Athena Bioscience Llc. It is protected by 2 US drug patents filed from 2021 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 01, 2040. Details of Qdolo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11103452 | Tramadol hydrochloride solution |
Sep, 2040
(16 years from now) | Active |
| US11752103 | Tramadol hydrochloride solution |
Sep, 2040
(16 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qdolo's patents.
Latest Legal Activities on Qdolo's Patents
Given below is the list of recent legal activities going on the following patents of Qdolo.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Email Notification | 12 Sep, 2023 | US11752103 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752103 |
| Recordation of Patent Grant Mailed | 12 Sep, 2023 | US11752103 |
| Patent Issue Date Used in PTA Calculation | 12 Sep, 2023 | US11752103 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752103 |
| Patent eGrant Notification | 12 Sep, 2023 | US11752103 |
| Email Notification | 24 Aug, 2023 | US11752103 |
| Issue Notification Mailed | 23 Aug, 2023 | US11752103 |
| Application Is Considered Ready for Issue | 10 Aug, 2023 | US11752103 |
| Dispatch to FDC | 10 Aug, 2023 | US11752103 |
US patents provide insights into the exclusivity only within the United States, but Qdolo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qdolo's family patents as well as insights into ongoing legal events on those patents.
Qdolo's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Qdolo's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 01, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qdolo Generics:
Tramadol Hydrochloride is the generic name for the brand Qdolo. 29 different companies have already filed for the generic of Qdolo, with Sun Pharm having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Qdolo's generic
About Qdolo
Qdolo is a drug owned by Athena Bioscience Llc. It is used for managing severe pain when alternative treatments are inadequate. Qdolo uses Tramadol Hydrochloride as an active ingredient. Qdolo was launched by Athena in 2020.
Market Authorisation Date:
Qdolo was approved by FDA for market use on 01 September, 2020.
Active Ingredient:
Qdolo uses Tramadol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Tramadol Hydrochloride ingredient
Treatment:
Qdolo is used for managing severe pain when alternative treatments are inadequate.
Dosage:
Qdolo is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/ML | SOLUTION | Prescription | ORAL |